Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 739-746

  Hoffman, Holly L ^a   Klepser, Michael E ^b   Ernst, Erika J ^a   Petzold, C Rosemarie ^a   Sa'adah, Loai Mohammed ^a   Doern, Gary V ^c  

^a UNIVERSITY OF IOWA   (United States)

^b FERRIS STATE UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; KAPLAN MEIER METHOD; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HALF-LIFE; HUMANS; LUNG DISEASES; MICE; MICROBIAL SENSITIVITY TESTS; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037308582     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.739-746.2003     Document Type: Article

References (20)

1. Andes, D., and W. A. Craig. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
2. Choi, E. H., and H. J. Lee. 1998. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin. Infect. Dis. 26:1346-1354.
3. Chu, S. Y., D. S. Wilson, D. R. Guay, and C. Craft. 1992. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J. Clin. Pharmacol. 32:1045-1049.
4. Conte, J. E., Jr., J. Golden, S. Duncan, E. McKenna, E. Lin, and E. Zurlinden. 1996. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. 40:1617-1622.
5. Conte, J. E., Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden. 1995. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents Chemother. 39:334-338.
6. Doern, G. V., A. Brueggemann, H. P. Holley, Jr., and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from out-patients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
7. Doern, G. V., A. B. Brueggemann, H. Huynh, and E. Wingert. 1999. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg. Infect. Dis. 5:757-765.
8. Heffelfinger, J. D., S. F. Dowell, J. H. Jorgensen, K. P. Klugman, L. R. Mabry, D. M. Musher, J. F. Plouffe, A. Rakowsky, A. Schuchat, and C. G. Whitney. 2000. Management of community-acquired, pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. 160:1399-1408.
9. Kohno, Y., K. Ohta, T. Suwa, and T. Suga. 1990. Autobacteriographic studies of clarithromycin and erythromycin in mice. Antimicrob. Agents Chemother. 34:562-567.
10. Moreno, S., M. E. Garcia-Leoni, E. Cercenado, M. D. Diaz, J. C. Bernaldo de Quiros, and E. Bouza. 1995. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin. Infect. Dis. 20:1195-1200.
11. National Committee for Clinical Laboratory Standards. 1998. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Pallares, R., J. Linares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
13. Patel, K. B., D. Xuan, P. R. Tessier, J. H. Russomanno, R. Quintiliani, and C. H. Nightingale. 1996. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40: 2375-2379.
14. Rodvold, K. A., M. H. Gotfried, L. H. Danziger, and R. J. Servi. 1997. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41:1399-1402.
15. Ruiz-Gonzalez, A., M. Falguera, A. Nogues, and M. Rubio-Caballero. 1999. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am. J. Med. 106:385-390.
16. Shortridge, V. D., G. V. Doern, A. B. Brueggemann, J. M. Beyer, and R. K. Flamm. 1999. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin. Infect. Dis. 29: 1186-1188.
17. Shortridge, V. D., R. K. Flamm, N. Ramer, J. Beyer, and S. K. Tanaka. 1996. Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 26:73-78.
18. Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:2251-2255.
19. Thornsberry, C., P. Ogilvie, J. Kahn, Y. Mauriz, et al. 1997. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn. Microbiol. Infect. Dis. 29:249-257.
20. Thornsberry, C., P. T. Ogilvie, H. P. Holley, Jr., and D. F. Sahm. 1999. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob. Agents Chemother. 43:2612-2623.